Immunotherapy Archives

norway cytovation cancer immuno oncology

News and Trends 26 Jan 2022

Norwegian Biotech Put on the Map with €18M Oncology Round

The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway’s biggest Series A rounds in life sciences. Historically, Norway’s biotech scene has not seen the kind of venture capital funding characteristic of health and biotech in the UK and US. However, Norwegian biotech is growing and has seen more successes than many […]

January 26, 2022 - 3 minutesmins - By Dan Samorodnitsky

London UK venture capital adendra therapeutics apple tree partners

News and Trends 14 Dec 2021

ATP Blazes US Venture Capital Trail into European Biotech Startups

The US venture capital firm Apple Tree Partners (ATP) is making its first transatlantic foray by launching the UK immuno-oncology company Adrendra Therapeutics. This happens as US investors increasingly search for value-for-money opportunities in early-stage European biotech startups. Last week, the life science-focused investor ATP contributed €47M (£40M) to the Series A launch of immunotherapy […]

December 14, 2021 - 4 minutesmins - By Anita Chakraverty

spatial transcriptomics, DNA, DNA double-helix, digital information

How is Spatial Transcriptomics Changing the Immuno-Oncology Field?

The advent of next-generation sequencing has led to the rise of novel gene expression profiling methods like spatial transcriptomics. How will this revolutionary approach, powered by high-quality multi-omics biospecimen, impact personalized immuno-oncology therapy in the future? Next-generation sequencing (NGS) technologies have revolutionized the way scientific research is conducted, triggering new research paradigms and providing novel […]

November 23, 2021 - 7 minutesmins - By Sudha Sundaram

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Jul 2021

Microbiome Medicines Could Power Up CAR-T Cell Therapies

The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A recent study conducted by researchers at Philipps-University Marburg, University Hospital Würzburg, and the Leeds-based company 4D Pharma showed that metabolites produced by the gut bacteria […]

July 28, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 26 Jul 2021

Europe’s TCR Therapy Scene Gains Traction with €40M Series B

Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies developing cell therapies for cancer based on engineering T-cell receptors (TCRs), known as TCR or TCR-T cell therapies. […]

July 26, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 8 Jul 2021

The Top European Biotech Funding Rounds in June

While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […]

July 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

dna sequencing covid 19 vaccine funding european biotech investment

News and Trends 10 Jun 2021

The Top European Biotech Investment Rounds in May

Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […]

June 10, 2021 - 4 minutesmins - By Jonathan Smith

Interview 26 May 2021

Immuno-Oncology: From Science Fiction to the Mainstream

In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […]

May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

spatial transcriptomics 10x genomics readcoor

In Depth 12 May 2021

Spatial Transcriptomics: A Window into Disease

The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease? DNA and RNA sequencing technology has undergone a revolution in the last decade, with companies working to provide ever cheaper and faster ways to explore our genetics. This stride […]

May 12, 2021 - 8 minutesmins - By Jonathan Smith

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us